Zoetis (NYSE:ZTS) Stock Rating Reaffirmed by Bank of America

Zoetis (NYSE:ZTS)‘s stock had its “hold” rating reiterated by Bank of America in a research report issued to clients and investors on Thursday, AnalystRatings.com reports. They presently have a $125.00 price target on the stock. Bank of America‘s price target indicates a potential upside of 2.69% from the stock’s previous close.

A number of other research analysts also recently weighed in on the company. Craig Hallum increased their price target on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Argus set a $140.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the stock a “buy” rating in a research note on Friday, September 13th. SunTrust Banks upped their price objective on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a report on Tuesday, August 13th. Finally, Barclays increased their target price on Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Zoetis currently has an average rating of “Buy” and an average price target of $125.53.

ZTS opened at $121.72 on Thursday. The company has a debt-to-equity ratio of 2.47, a current ratio of 4.39 and a quick ratio of 3.02. The company has a market cap of $57.98 billion, a price-to-earnings ratio of 38.89, a price-to-earnings-growth ratio of 2.76 and a beta of 0.80. The firm has a 50 day simple moving average of $121.90 and a 200 day simple moving average of $118.82. Zoetis has a fifty-two week low of $78.90 and a fifty-two week high of $130.20.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same period last year, the firm earned $0.83 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, analysts expect that Zoetis will post 3.6 EPS for the current year.

In other Zoetis news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $120.05, for a total value of $735,066.15. Following the completion of the sale, the executive vice president now directly owns 41,698 shares in the company, valued at $5,005,844.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Juan Ramon Alaix sold 50,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $119.13, for a total value of $5,956,500.00. Following the completion of the sale, the chief executive officer now owns 146,013 shares of the company’s stock, valued at $17,394,528.69. The disclosure for this sale can be found here. Over the last three months, insiders have sold 130,040 shares of company stock worth $15,554,852. Insiders own 0.29% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ZTS. AE Wealth Management LLC acquired a new position in shares of Zoetis in the second quarter valued at approximately $494,000. Ballentine Partners LLC acquired a new stake in Zoetis in the 2nd quarter valued at $312,000. Steward Partners Investment Advisory LLC lifted its position in Zoetis by 22.8% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 11,522 shares of the company’s stock worth $1,307,000 after buying an additional 2,141 shares in the last quarter. Creative Planning lifted its position in Zoetis by 4.5% during the 2nd quarter. Creative Planning now owns 16,532 shares of the company’s stock worth $1,876,000 after buying an additional 719 shares in the last quarter. Finally, Trust Co. of Vermont lifted its position in Zoetis by 12.4% during the 2nd quarter. Trust Co. of Vermont now owns 914 shares of the company’s stock worth $104,000 after buying an additional 101 shares in the last quarter. Institutional investors and hedge funds own 90.17% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: Monthly Dividend Stocks Can Provide Solid Income

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.